Latest Administration News

One Click Group Limited has reported a record-breaking July with $3 million in revenue and $1.4 million in EBIT, marking a 34% increase on the prior period and profitability for the first seven months of 2025.

EBR Systems has secured FDA approval for its pioneering leadless WiSE CRT System and obtained key Medicare reimbursement endorsements, setting the stage for its commercial rollout. The company also completed a significant capital raise to support its market expansion.

Insurance Australia Group (IAG) reported a robust FY25 with strong premium growth, improved margins, and strategic acquisitions pending regulatory approval. The company projects continued growth and margin stability into FY26.

Nutritional Growth Solutions Ltd has clarified discrepancies in its June 2025 quarterly reports, attributing changes to timing and classification adjustments, while reaffirming its financial health and governance compliance.

WAM Capital Limited’s July 2025 update reveals a robust net tangible asset position and a healthy interim dividend, underpinned by strong performances from key holdings ALS and HUB24.

Opyl Limited has formalized its partnership with UK-based Innovatrix Capital, positioning its AI platform TrialKey at the forefront of clinical trial failure insurance. This deal not only validates Opyl’s technology but also opens doors to global biotech markets and valuable data streams.

Platinum Asia Investments Limited (PAI) held a pivotal Scheme Meeting seeking shareholder approval to restructure by exchanging shares for units in the Platinum Asia Fund Complex ETF (PAXX), accompanied by a special dividend payment. The outcome will reshape PAI’s investment management and ownership structure.

Resouro Strategic Metals reports a significant update to its Tiros project resource alongside a reduced quarterly loss, highlighting progress in its Brazilian exploration assets.

Anteris Technologies reported solid clinical progress with 130 patients implanted with its DurAVR heart valve and is gearing up for its pivotal PARADIGM trial with 79 qualified sites worldwide. The company also strengthened its leadership with two new board members amid ongoing FDA engagement.

Audeara Limited has secured a five-year licensing agreement with Eastech (Huizhou) Co., Ltd. to bring its advanced hearing technology to China’s booming medical device market, leveraging major e-commerce platforms for distribution.

Island Pharmaceuticals has raised $350,000 through an options exercise by substantial shareholder MWP Partners, reinforcing confidence in its antiviral drug development pipeline.

Syntara Limited has received FDA guidance recommending a Phase 2 controlled trial for its lead drug amsulostat in myelofibrosis, setting the stage for a pivotal Phase 3 study. The company is poised to refine its clinical strategy while advancing a diverse pipeline with key data milestones ahead.